PT Pyridam Farma Tbk (ISX:PYFA) Research & Development: Rp22,359 Mil (TTM As of Mar. 2026)


ISX:PYFA PT Pyridam Farma Tbk ISX:PYFA
68 GF Score
Price Rp182.00
GF Value Rp212.90
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is PT Pyridam Farma Tbk Research & Development?

PT Pyridam Farma Tbk ISX:PYFA -1.09% 68 Research & Development is Rp22,359 Mil as of Mar. 2026. GuruFocus rates ISX:PYFA with a GF Score™ of 68/100 and a GF Value™ of Rp212.90 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PT Pyridam Farma Tbk's Research & Development for the three months ended in Mar. 2026 was Rp6,077 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was Rp22,359 Mil.

PT Pyridam Farma Tbk  (ISX:PYFA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Pyridam Farma Tbk Research & Development Related Terms

PT Pyridam Farma Tbk Research & Development Historical Data

* Premium members only.

The historical data trend for PT Pyridam Farma Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Pyridam Farma Tbk Research & Development Chart

PT Pyridam Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 573.44 11,280.07 17,765.49 17,615.11 21,540.93

PT Pyridam Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,258.96 10,249.64 7,876.45 -1,844.13 6,076.95
ISX:PYFA
68GF Score
PT Pyridam Farma Tbk ISX:PYFA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Pyridam Farma Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp22,359 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Rp22,359 Mil mean?
PT Pyridam Farma Tbk (ISX:PYFA) has a Research & Development of Rp22,359 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Research & Development too high?
PT Pyridam Farma Tbk's current Research & Development is Rp22,359 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Research & Development compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Research & Development of Rp22,359 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Research & Development is Rp22,359 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp212.90, compared to a current price of Rp182.00 — trading 14.5% below its estimated fair value. The current Research & Development is Rp22,359 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Research & Development is Rp22,359 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued. The current stock price of Rp182.00 is trading 14.5% below its estimated GF Value™ of Rp212.90. GuruFocus considers PT Pyridam Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:PYFA:

  • Research & Development: Rp22,359 Mil
  • GF Value™: Rp212.90 vs. price of Rp182.00 (14.5% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Pyridam Farma Tbk Business Description

Address Jl. Jenderal Sudirman Kav. 21, Sinar Mas Land Plaza Sudirman 12th Floor, RT 10/RW 01 Kuningan, Karet, Jakarta Selatan, Jakarta, IDN, 12920
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
68GF Score

Get the complete analysis for ISX:PYFA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp182.00
Price
Rp212.90
GF Value